Farmácia/Notícias da Indústria
Estudo randomizado | Comparação da cetamina nebulizada em 3 regimes de dose diferentes para o tratamento de condições dolorosas no departamento de emergência.
13 Jul, 2021 | 11:11hComparison of Nebulized Ketamine at Three Different Dosing Regimens for Treating Painful Conditions in the Emergency Department: A Prospective, Randomized, Double-Blind Clinical Trial – Annals of Emergency Medicine (link para o resumo – $ para o texto completo)
Comentário no Twitter
Nebulized Ketamine for pain in the ED? No way…Well- here you go-Comparison of Nebulized Ketamine at Three Different Dosing Regimens for Treating Painful Conditions in the ED. https://t.co/v3UT0Y0LdU #FOAMed #FOAMems #FOAMtox #FOAMcc #FOAMpharm
— Sergey Motov (@painfreeED) July 3, 2021
[Preprint] Heparina para pacientes com Covid-19 moderada – “Em pacientes com Covid-19 moderada e D-dímero elevado, a terapia com heparina não reduziu significativamente o desfecho primário, mas reduziu as chances de morte em 28 dias de doença.”
12 Jul, 2021 | 11:41hHeparin for Moderately Ill Patients with Covid-19 – medRxiv
Relacionado: RCT: In patients hospitalized with Covid-19 with elevated D-Dimer, a full-dose anticoagulation strategy based on rivaroxaban (full-dose heparins in unstable patients) + rivaroxaban to day 30 was not better than prophylactic anticoagulation and increased bleeding risk. E [Preprint] Practice Changing RCT: Therapeutic-dose anticoagulation with heparin (LMWH or unfractionated heparin) improves outcomes in non-critically ill patients with Covid-19 – the superiority of therapeutic-dose anticoagulation was seen in both high and low D-dimer groups. E [Preprint] RCT: Full-dose/therapeutic anticoagulation provides no benefit in critically ill patients with Covid-19
Comentário no Twitter (fio – clique para saber mais)
🚨Final results of the RAPID trial now pub'd @medrxivpreprint 🚨 RAPID was an open-label trial that randomly assigned hospitalized ward patients with COVID-19 and elevated D-dimer levels to therapeutic or prophylactic heparin. 🧵 1/10 https://t.co/oxiyXQAPeK pic.twitter.com/V2GtruEyM2
— Michelle Sholzberg (@sholzberg) July 9, 2021
Estudo randomizado | Outro estudo mostra que a azitromicina não melhora os desfechos em pacientes com Covid-19.
12 Jul, 2021 | 11:37hComentários: Trial shows that the antibiotic azithromycin does not prevent mild COVID cases progressing to hospitalization, death – European Society of Clinical Microbiology and Infectious Diseases E Azithromycin: can its benefit be ruled out in mild COVID-19? – The Lancet Respiratory Medicine
Relacionado: M-A: Azithromycin does not reduce the need for invasive mechanical ventilation or mortality in patients with Covid-19. E RCT: Azithromycin provides no benefit for community treatment of patients with suspected COVID-19 E RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19 E E Coalition Covid-19 Brazil – Randomized trial: Azithromycin not beneficial for patients admitted to the hospital with severe Covid-19 E Coalition Covid-19 Brazil – Randomized trial: hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19
Comentário no Twitter
In patients with mild-to-mod #COVID19 managed without hospital admission, azithromycin + SOC did not reduce the risk of subsequent hospital admission or death
Read the ATOMIC2 trial here https://t.co/QXJ7T08JZS, being presented at #ECCMID2021 by lead author Tim Hinks @HinksLab pic.twitter.com/ZDiPhuQqFB
— The Lancet Respiratory Medicine (@LancetRespirMed) July 9, 2021
Pfizer afirma que é hora de um reforço (terceira dose) na vacina contra a Covid; FDA e CDC dizem que ainda não.
12 Jul, 2021 | 11:35hPfizer says it’s time for a Covid booster; FDA and CDC say not so fast – CNN
Ver também: CDC, FDA contradict Pfizer on COVID-19 vaccine booster – CIDRAP E Do I need a COVID-19 booster shot? 6 questions answered on how to stay protected – The Conversation E Pfizer suggests booster shots will be needed this year, but government officials say science will dictate the timing – The Washington Post E Pfizer to seek OK for 3rd vaccine dose; shots still protect – Associated Press E Citing the Delta Variant, Pfizer Will Pursue Booster Shots and a New Vaccine – The New York Times (poucos artigos gratuitos por mês) E Question open on need for COVID booster shot, data awaited, WHO says – Reuters
É possível aplicar doses menores das vacinas já existentes contra a Covid para inocular mais pessoas? Os especialistas estão divididos.
12 Jul, 2021 | 11:32hCan we stretch existing Covid vaccines to inoculate more people? Experts are divided – STAT
Ver também: Quarter-dose of Moderna COVID vaccine still rouses a big immune response
OMS afirma que os benefícios das vacinas de mRNA contra a COVID são superiores aos raros riscos cardíacos.
12 Jul, 2021 | 11:30hBenefits of mRNA COVID vaccines outweigh rare heart risks, says WHO – Reuters
Ver também: EU finds potential link between heart inflammation and mRNA COVID shots – Reuters E Heart inflammation link to Pfizer and Moderna jabs – BBC
Ranitidina absolvida? Estudo do FDA mostra que a ranitidina não é convertida ao carcinógeno NDMA, independentemente da dieta.
12 Jul, 2021 | 11:23hEditorial: Ranitidine and Risk of N-Nitrosodimethylamine (NDMA) Formation
Comentário: Ranitidine: FDA finds no evidence of elevated NDMA, regardless of diet
Comentário no Twitter
Despite ranitidine (zantac) being pulled from market last year, a new study from the FDA did not find evidence that it increases concentrations of the carcinogenic metabolite people were worried about (i.e., it's probably safe). From @JAMA_current https://t.co/AdRic2GdXS
— Zack Williams (@QuantPsychiatry) June 28, 2021
In this crossover, randomized clinical trial, oral ranitidine did not significantly increase 24-hour urinary excretion of NDMA when administered with a noncured-meats diet or a cured-meats diet. https://t.co/EszRvfJOFJ
— JAMA (@JAMA_current) June 28, 2021
Estudo randomizado | Outro estudo mostra a segurança do tratamento ambulatorial sem antibióticos na diverticulite aguda leve.
12 Jul, 2021 | 11:19hEfficacy and Safety of Non-Antibiotic Outpatient Treatment in Mild Acute Diverticulitis (DINAMO-study): A Multicentre, Randomised, Open-Label, Non-Inferiority Trial – Annals of Surgery (link para o resumo – $ para o texto completo)
Relacionado: State of the Art Review: Management of colonic diverticulitis E Treatment of Uncomplicated Acute Diverticulitis Without Antibiotics: A Systematic Review and Meta-analysis – Diseases of the Colon & Rectum E Antibiotics Do Not Reduce Length of Hospital Stay for Uncomplicated Diverticulitis in a Pragmatic Double-Blind Randomized Trial – Clinical Gastroenterology and Hepatology E Randomized Trial: Antibiotic Avoidance Associated with Similar Long-term Outcomes in Uncomplicated Diverticulitis
Comentário no Twitter
Another (final?) nail in the coffin for antibiotics in uncomplicated diverticulitis? DINAMO study from Spain – Outpatient treatment with antibiotics versus symptomatic Tx.
No difference in hospitalization rate or revisits to ER.https://t.co/wOc3tBGfxr @AnnalsofSurgery
— Ville Sallinen (@villesallinen) July 9, 2021
Editorial | Aducanumabe para doença de Alzheimer?
12 Jul, 2021 | 11:13hAducanumab for Alzheimer’s disease? – The BMJ
Relacionado: FDA approvement of Alzheimer’s drug sparks controversy among doctors.
Comentário no Twitter
Our editorial for @bmj_latest on the controversial #Aducanumab approval and what it means for patients, clinicians and researchers.
With @seb_walsh, Richard Milne @ethicsWCS, Carol Brayne @CamPubHealth https://t.co/mnhh4F1gKK— Richard Merrick (@r_merrick) July 9, 2021
Estudo randomizado | CoronaVac mostrou eficácia de 83,5% na prevenção de infecção sintomática por SARS-CoV-2.
9 Jul, 2021 | 16:13hComentário convidado: CoronaVac: more data for regulators and policy makers
Comentário no Twitter
NEW—Interim analysis from phase 3 trial suggests efficacy of 2 doses of #CoronaVac is 83.5% against symptomatic #COVID19. More research is needed to confirm efficacy in the long term, in a more diverse group, and against emerging #variants of concern.
🔗 https://t.co/TN5b6wwclc pic.twitter.com/4zOvJFIIOH
— The Lancet (@TheLancet) July 8, 2021